Fiche traitement
Levodopa
Emory University • Parkinson
Suivi actif
Phase 4
Résumé
Levodopa est développé par Emory University. Le traitement est actuellement en Phase 4. Il est associé à Parkinson. Son objectif thérapeutique principal est À vérifier. Le statut actuel est : suivi actif.
À vérifier
À vérifier
Phase 4
Emory University
United States
Patients with Parkinson's Disease will be studied before, during, and after a deep brain stimulation implantation procedure to see if the stimulation location and the size of the electrical field produced by subthalamic nucleus (STN) DBS determine the degree to which DBS engages circuits that involve prefrontal cortex executive functions, and therefore have a direct impact on the patient's ability to inhibit actions.
2026-09-01
Début phase actuelle
Non disponible dans les sources synchronisées
Timeline clinique
Phase 4
Début phase actuelle
Non disponible dans les sources synchronisées
Préclinique
Phase 1
Phase 2
Phase 3
Approuvé
Objectif scientifique de l’étude
classification automatique vérifiable
À vérifier
Confiance automatique : 0%
Ce pourcentage n’est pas une probabilité de succès clinique.
Il mesure uniquement la force de la classification automatique de l’objectif scientifique. Le calcul part de 45 points, ajoute 7 points par unité de poids du mot-clé le plus fortement détecté, puis est plafonné à 95 %. Exemple : un score maximal de 2 donne 45 + (2 × 7) = 59 %.
Ce score est heuristique et doit être vérifié dans le protocole ou une publication.
Description affichée depuis l’essai compatible NCT06234995, afin d’éviter le mélange entre plusieurs indications d’une même molécule.
Contrôle de cohérence : 85/100
L’objectif est absent ou classé « Autre » et doit être recalculé à partir du protocole.
Transparence et qualité de la fiche
données vérifiablesClassificationÀ vérifier
Confiance de la fiche85 %
Source principaleSource officielle ou publication indexée
Dernière vérification2026-09-01
Anomalies détectées1
Validation humaineValidation humaine non effectuée
Donnée issue d’une source
Donnée normalisée automatiquement
Interprétation algorithmique
Classification scientifique multi-axes
ne pas confondre statut et résultatÉtat de l’étudeRecrutement en cours
Disponibilité des résultatsRésultats à vérifier
InterprétationImpossible à déterminer
Niveau de preuveNon évaluable
Un essai terminé n’est pas nécessairement positif. Un essai arrêté n’est classé comme échec scientifique que lorsqu’un résultat ou une raison explicite le confirme.
Indicateurs factuels
sans score subjectifPhase enregistréePhase 4
Études associées1
Publications associées44
Statut consolidéSuivi actif
Aucune chance de succès, note d’innovation, potentiel thérapeutique ou probabilité de commercialisation n’est calculé tant qu’un modèle validé et des données suffisantes ne sont pas disponibles.
Historique factuel de la molécule
48 événement(s) daté(s)Cette liste reprend uniquement les dates trouvées dans les registres et publications liés. Elle ne constitue pas une prévision.
| Date | Événement | Source |
|---|---|---|
| 2021-08-09 | Début de l’étudeNCT06234995 | Registre d’essai clinique |
| 2026-07-08 | PublicationClinical Efficacy and Dosing of Vibrotactile Coordinated Reset Stimulation in Motor and Non-motor Symptoms of Parkinson's Disease: A Study Protocol. | Frontiers in neurology |
| 2026-07-08 | PublicationExtrapontine Myelinolysis and Reversible Parkinsonism After Hyponatremia Correction in a Case of Pituitary Adenoma: Hypopituitarism as a Predisposition for Osmotic Demyelination. | World neurosurgery |
| 2026-07-08 | PublicationFoslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease. | Annals of neurology |
| 2026-07-10 | PublicationIn brief: New warnings for carbidopa/levodopa products. | The Medical letter on drugs and therapeutics |
| 2026-07-10 | PublicationPharmacokinetics and Tolerability of Entacapone, Levodopa, and Carbidopa Tablets in Healthy Chinese Subjects: A Randomized, Open-Label, Four-Period Crossover Study Under Fasting and Fed Conditions. | Clinical pharmacology in drug development |
| 2026-07-10 | PublicationCVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial. | EClinicalMedicine |
| 2026-07-12 | PublicationState-dependent gut-brain electrophysiological coupling tracks motor complication severity in Parkinson's disease. | Bio Systems |
| 2026-07-12 | PublicationFormulation and clinical evaluation of carbidopa/levodopa oral solution for the treatment of sepiapterin reductase deficiency. | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V |
| 2026-07-12 | PublicationFoslevodopa/Foscarbidopa: A Review in Advanced Parkinson's Disease. | CNS drugs |
| 2026-07-14 | PublicationBehavioral Effects of Renin-Angiotensin System Modulators in a Rotenone-Induced Model of Parkinson's Disease in Wistar Albino Rats. | Cureus |
| 2026-07-18 | PublicationHow to dose extended-release carbidopa-levodopa capsules (IPX203, CREXONT®) in patients with Parkinson's disease. | Clinical parkinsonism & related disorders |
| 2026-07-18 | PublicationEfficacy and safety of IPX203 in Parkinson's patients: a systematic review and meta-analysis. | Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology |
| 2026-07-18 | PublicationTreatment strategies for motor fluctuations in Parkinson's disease: a systematic review of efficacy, functionality, and drug accessibility with a focus on Latin America. | Frontiers in pharmacology |
| 2026-07-22 | PublicationA long-term follow-up of safety and clinical efficacy of NTCELL® [Immunoprotected (Alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease. | Parkinsonism & related disorders |
| 2026-08-08 | PublicationIndirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease 'OFF' episodes. | Journal of comparative effectiveness research |
| 2026-08-08 | PublicationJuvenile Parkinson's disease: Symptom burden and treatment challenges. | Journal of Parkinson's disease |
| 2026-08-08 | PublicationEfficacy of citicoline as an add-on therapy in Parkinson's disease: a randomized, double-blind trial. | Parkinsonism & related disorders |
| 2026-08-08 | PublicationChallenges of Pain in Parkinson's Disease: Results from the OCEAN Study. | Movement disorders : official journal of the Movement Disorder Society |
| 2026-08-08 | PublicationEffect of COMT and UGT1A Variants on Clinical Response to Opicapone in Parkinson's Disease. | Movement disorders clinical practice |
| 2026-08-08 | PublicationEffect of LRRK2 G2385R Variant on Subthalamic Deep Brain Stimulation Efficacy in Parkinson's Disease in a Han Chinese Population. | Frontiers in neurology |
| 2026-08-08 | PublicationData on the effect of Parkinson's disease multimodal complex treatment in a German University Hospital. | Data in brief |
| 2026-08-08 | PublicationSix-Year Single Centre Experience with Frameless, Fiducial-Less Deep Brain Stimulation in Parkinsons Disease: Accuracy, Outcomes, and Clinical Feasibility. | Stereotactic and functional neurosurgery |
| 2026-08-08 | PublicationReproducible Generalized Thermal Sensation Triggered by Levodopa in a Patient With Parkinson's Disease. | Journal of medical cases |
| 2026-08-13 | PublicationSublingual apomorphine in the treatment of Parkinson's disease. | Journal of neural transmission (Vienna, Austria : 1996) |
| 2026-08-13 | PublicationInsights into retention and safety/tolerability of apomorphine sublingual film in patients with Parkinson's disease and OFF episodes: post hoc analyses of a phase III, open-label study. | Therapeutic advances in neurological disorders |
| 2026-08-13 | PublicationThe effect of levodopa or levodopa-carbidopa (sinemet) on fracture healing. | Journal of orthopaedic trauma |
| 2026-08-13 | PublicationPharmaceutical and pharmacokinetic evaluation of a newly formulated multiparticulate matrix of levodopa and carbidopa. | ADMET & DMPK |
| 2026-08-13 | PublicationSafety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial. | The Lancet. Neurology |
| 2026-08-13 | PublicationAdd-on safinamide and amantadine in Filipino Parkinson's disease patients with motor fluctuations: a retrospective exploratory cohort study. | Journal of neural transmission (Vienna, Austria : 1996) |
| 2026-08-16 | PublicationSubcutaneous foslevodopa/foscarbidopa (LDp/CDp) in advanced Parkinson's disease (aPD): societal cost impact analysis for the UK, France, Germany, Spain, and Canada. | Journal of medical economics |
| 2026-08-16 | PublicationHistorical Perspectives of Parkinson's Disease: Early Clinical Descriptions and Neurological Therapies. | Cold Spring Harbor perspectives in medicine |
| 2026-08-16 | PublicationThe catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. | Journal of neurology, neurosurgery, and psychiatry |
| 2026-08-16 | PublicationOpen-label titration of apomorphine sublingual film in patients with Parkinson's disease and "OFF" episodes. | Parkinsonism & related disorders |
| 2026-08-16 | PublicationObservational Retrospective Cohort of Patient Support Program Data on Practical Experiences of Treatment with Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: The ORCHESTRA Study. | Neurology and therapy |
| 2026-08-16 | PublicationRecent Developments in the Drug Treatment of Parkinson's Disease. | Drugs |
| 2026-08-16 | PublicationAdvanced Parkinson's disease treatment patterns in Italy: results from a multicenter observational study. | Annals of medicine |
| 2026-08-16 | PublicationZonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: A retrospective, observational cohort study. | Journal of the neurological sciences |
| 2026-08-16 | PublicationStudy of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. | Movement disorders : official journal of the Movement Disorder Society |
| 2026-08-16 | PublicationClinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. | Movement disorders : official journal of the Movement Disorder Society |
| 2026-08-16 | PublicationDuration of "Good On" time per dose: Immediate-release carbidopa-levodopa vs. extended-release carbidopa-levodopa (IPX203, CREXONT®). | Parkinsonism & related disorders |
| 2026-08-16 | PublicationRandomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. | Parkinsonism & related disorders |
| 2026-08-16 | PublicationResolving spectral overlaps in Anti-Parkinson drug combinations: a green spectrophotometric approach for entacapone determination. | BMC chemistry |
| 2026-08-16 | PublicationIsolated extra pontine myelinolysis presenting as acute onset parkinsonism. | BMJ case reports |
| 2026-09-01 | Dernière mise à jour des donnéesLevodopa | Biomedical Watch |
| 2026-09-03 | Création de l’enregistrementNCT06234995 | Registre d’essai clinique |
| 2026-09-11 | PublicationReversible exacerbation of parkinsonism during epirubicin-cyclophosphamide chemotherapy in a patient with PTEN hamartoma tumor syndrome and young-onset Parkinson's disease. | Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology |
| 2027-09-01 | Fin de l’étude prévue / enregistréeNCT06234995 | Registre d’essai clinique |
Début phase actuelle
Non disponible dans les sources synchronisées
Essais cliniques liés
1 essai(s)
Début phase actuelle
Non disponible dans les sources synchronisées
| NCT | Titre | Phase | Statut administratif | Pays | Sponsor |
|---|---|---|---|---|---|
| NCT06234995 | Cortical Electrophysiology of Response Inhibition in Parkinson's Disease | Phase 4 | RECRUITING | United States | Emory University |
Publications liées
44 publication(s)Publications liées
44 publication(s)| Titre | PMID | DOI | Journal | Date |
|---|---|---|---|---|
| Reversible exacerbation of parkinsonism during epirubicin-cyclophosphamide chemotherapy in a patient with PTEN hamartoma tumor syndrome and young-onset Parkinson's disease. Voir source | 42726292 | 10.1007/s10072-026-09361-1 | Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology | |
| Subcutaneous foslevodopa/foscarbidopa (LDp/CDp) in advanced Parkinson's disease (aPD): societal cost impact analysis for the UK, France, Germany, Spain, and Canada. Voir source | 42047110 | 10.1080/13696998.2026.2652780 | Journal of medical economics | |
| Historical Perspectives of Parkinson's Disease: Early Clinical Descriptions and Neurological Therapies. Voir source | 38858084 | 10.1101/cshperspect.a041642 | Cold Spring Harbor perspectives in medicine | |
| The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. Voir source | 10766888 | 10.1136/jnnp.68.5.589 | Journal of neurology, neurosurgery, and psychiatry | |
| Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and "OFF" episodes. Voir source | 32927285 | 10.1016/j.parkreldis.2020.08.028 | Parkinsonism & related disorders | |
| Observational Retrospective Cohort of Patient Support Program Data on Practical Experiences of Treatment with Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: The ORCHESTRA Study. Voir source | 42322391 | 10.1007/s40120-026-00978-0 | Neurology and therapy | |
| Recent Developments in the Drug Treatment of Parkinson's Disease. Voir source | 42162439 | 10.1007/s40265-026-02327-9 | Drugs | |
| Advanced Parkinson's disease treatment patterns in Italy: results from a multicenter observational study. Voir source | 41782314 | 10.1080/07853890.2026.2628353 | Annals of medicine | |
| Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: A retrospective, observational cohort study. Voir source | 30103971 | 10.1016/j.jns.2018.05.013 | Journal of the neurological sciences | |
| Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Voir source | 18831530 | 10.1002/mds.22095 | Movement disorders : official journal of the Movement Disorder Society | |
| Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. Voir source | 20629136 | 10.1002/mds.23107 | Movement disorders : official journal of the Movement Disorder Society | |
| Duration of "Good On" time per dose: Immediate-release carbidopa-levodopa vs. extended-release carbidopa-levodopa (IPX203, CREXONT®). Voir source | 39733558 | 10.1016/j.parkreldis.2024.107239 | Parkinsonism & related disorders | |
| Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Voir source | 24055014 | 10.1016/j.parkreldis.2013.08.017 | Parkinsonism & related disorders | |
| Resolving spectral overlaps in Anti-Parkinson drug combinations: a green spectrophotometric approach for entacapone determination. Voir source | 41917978 | 10.1186/s13065-026-01768-3 | BMC chemistry | |
| Isolated extra pontine myelinolysis presenting as acute onset parkinsonism. Voir source | 23076704 | 10.1136/bcr-2012-007140 | BMJ case reports | |
| Sublingual apomorphine in the treatment of Parkinson's disease. Voir source | 38743091 | 10.1007/s00702-024-02777-z | Journal of neural transmission (Vienna, Austria : 1996) | |
| Insights into retention and safety/tolerability of apomorphine sublingual film in patients with Parkinson's disease and OFF episodes: post hoc analyses of a phase III, open-label study. Voir source | 40547865 | 10.1177/17562864251343583 | Therapeutic advances in neurological disorders | |
| The effect of levodopa or levodopa-carbidopa (sinemet) on fracture healing. Voir source | 16891938 | 10.1097/00005131-200608000-00004 | Journal of orthopaedic trauma | |
| Pharmaceutical and pharmacokinetic evaluation of a newly formulated multiparticulate matrix of levodopa and carbidopa. Voir source | 36778908 | 10.5599/admet.1474 | ADMET & DMPK | |
| Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial. Voir source | 38499015 | 10.1016/S1474-4422(24)00052-8 | The Lancet. Neurology | |
| Add-on safinamide and amantadine in Filipino Parkinson's disease patients with motor fluctuations: a retrospective exploratory cohort study. Voir source | 42550256 | 10.1007/s00702-026-03246-5 | Journal of neural transmission (Vienna, Austria : 1996) | |
| Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease 'OFF' episodes. Voir source | 35068168 | 10.2217/cer-2021-0178 | Journal of comparative effectiveness research | |
| Juvenile Parkinson's disease: Symptom burden and treatment challenges. Voir source | 42555091 | 10.1177/1877718X261473047 | Journal of Parkinson's disease | |
| Efficacy of citicoline as an add-on therapy in Parkinson's disease: a randomized, double-blind trial. Voir source | 42561742 | 10.1016/j.parkreldis.2026.108911 | Parkinsonism & related disorders | |
| Challenges of Pain in Parkinson's Disease: Results from the OCEAN Study. Voir source | 42259665 | 10.1002/mds.70390 | Movement disorders : official journal of the Movement Disorder Society | |
| Effect of COMT and UGT1A Variants on Clinical Response to Opicapone in Parkinson's Disease. Voir source | 42473901 | 10.1002/mdc3.70751 | Movement disorders clinical practice | |
| Effect of LRRK2 G2385R Variant on Subthalamic Deep Brain Stimulation Efficacy in Parkinson's Disease in a Han Chinese Population. Voir source | 31824408 | 10.3389/fneur.2019.01231 | Frontiers in neurology | |
| Data on the effect of Parkinson's disease multimodal complex treatment in a German University Hospital. Voir source | 35959469 | 10.1016/j.dib.2022.108496 | Data in brief | |
| Six-Year Single Centre Experience with Frameless, Fiducial-Less Deep Brain Stimulation in Parkinsons Disease: Accuracy, Outcomes, and Clinical Feasibility. Voir source | 42525602 | 10.1159/000552756 | Stereotactic and functional neurosurgery | |
| Reproducible Generalized Thermal Sensation Triggered by Levodopa in a Patient With Parkinson's Disease. Voir source | 42564325 | 10.14740/jmc5357 | Journal of medical cases | |
| A long-term follow-up of safety and clinical efficacy of NTCELL® [Immunoprotected (Alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease. Voir source | 33321452 | 10.1016/j.parkreldis.2020.12.005 | Parkinsonism & related disorders | |
| How to dose extended-release carbidopa-levodopa capsules (IPX203, CREXONT®) in patients with Parkinson's disease. Voir source | 40799912 | 10.1016/j.prdoa.2025.100357 | Clinical parkinsonism & related disorders | |
| Efficacy and safety of IPX203 in Parkinson's patients: a systematic review and meta-analysis. Voir source | 41565857 | 10.1007/s10072-025-08692-9 | Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology | |
| Treatment strategies for motor fluctuations in Parkinson's disease: a systematic review of efficacy, functionality, and drug accessibility with a focus on Latin America. Voir source | 41415581 | 10.3389/fphar.2025.1725248 | Frontiers in pharmacology | |
| Behavioral Effects of Renin-Angiotensin System Modulators in a Rotenone-Induced Model of Parkinson's Disease in Wistar Albino Rats. Voir source | 42317891 | 10.7759/cureus.109052 | Cureus | |
| State-dependent gut-brain electrophysiological coupling tracks motor complication severity in Parkinson's disease. Voir source | 42203101 | 10.1016/j.biosystems.2026.105835 | Bio Systems | |
| Formulation and clinical evaluation of carbidopa/levodopa oral solution for the treatment of sepiapterin reductase deficiency. Voir source | 39097116 | 10.1016/j.ejpb.2024.114429 | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V | |
| Foslevodopa/Foscarbidopa: A Review in Advanced Parkinson's Disease. Voir source | 40198538 | 10.1007/s40263-025-01179-3 | CNS drugs | |
| In brief: New warnings for carbidopa/levodopa products. Voir source | 42024127 | 10.58347/tml.2026.1753b | The Medical letter on drugs and therapeutics | |
| Pharmacokinetics and Tolerability of Entacapone, Levodopa, and Carbidopa Tablets in Healthy Chinese Subjects: A Randomized, Open-Label, Four-Period Crossover Study Under Fasting and Fed Conditions. Voir source | 42212550 | 10.1002/cpdd.70071 | Clinical pharmacology in drug development | |
| CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial. Voir source | 39469536 | 10.1016/j.eclinm.2024.102882 | EClinicalMedicine | |
| Clinical Efficacy and Dosing of Vibrotactile Coordinated Reset Stimulation in Motor and Non-motor Symptoms of Parkinson's Disease: A Study Protocol. Voir source | 34867742 | 10.3389/fneur.2021.758481 | Frontiers in neurology | |
| Extrapontine Myelinolysis and Reversible Parkinsonism After Hyponatremia Correction in a Case of Pituitary Adenoma: Hypopituitarism as a Predisposition for Osmotic Demyelination. Voir source | 30055367 | 10.1016/j.wneu.2018.07.115 | World neurosurgery | |
| Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease. Voir source | 33772855 | 10.1002/ana.26073 | Annals of neurology |
Sources officielles
liens de rechercheDernière mise à jour des données : 2026-09-01
Ces sources sont proposées pour vérification. Les informations de la fiche doivent être confirmées dans les registres officiels ou les publications originales.